ImmunityBio issues $30M convertible promissory note to Nant Capital, LLC

ImmunityBio, Inc.

$30M principal, Term SOFR + 8% interest, due Dec 31, 2023.
Investor is Nant Capital, LLC, affiliated with Executive Chairman Dr. Patrick Soon-Shiong.
Net proceeds $29.85M after 0.5% origination fee; funds for pre-commercialization, R&D, and corporate purposes.
Convertible at holder's option after next insider trading window opens at greater of Nasdaq closing or bid price.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ImmunityBio, Inc. entered into $30.0 million convertible promissory note with Nant Capital, LLC valued at $30.0 million (effective 2023-03-31).

Action: entry
Agreement: notes offering
Counterparty: Nant Capital, LLC
Value: $30.0 million
Effective: 2023-03-31

Exact text from the filing

On March 31, 2023, ImmunityBio, Inc. (the “Company”) executed a $30.0 million convertible promissory note with Nant Capital, LLC

View on SEC.gov

Browse all material agreements →

ImmunityBio, Inc. filing history →

Source: SEC EDGAR

accession 0001326110-23-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.